Kathrin Bernt, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz

Kathrin Bernt, University of Colorado Anschutz Medical Campus

Caption

Kathrin Bernt, MD, and colleagues show how MN1 drives aggressive AML subtype, implying possible benefit from existing drug.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.